Conditions: PI3K Pathway Activated Tumors
Keywords: Solid tumor malignancy hematologic malignancy PI3K pathway activation P13K activated tumors BKM120 signature AML acute myelogenous leukemia cervical ovarian hepatobiliary buparlisib
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 146
Healthy volunteers: no

Brief summary:
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.

Detailed description:

Arms:
arm 1: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle

Interventions: intervention 1: BKM120
Intervention descriptions: intervention 1: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle

Protocol document: